Mesoblast (NASDAQ:MESO - Get Free Report) is expected to be posting its quarterly earnings results on Thursday, February 27th. Analysts expect Mesoblast to post earnings of ($0.25) per share and revenue of $2.39 million for the quarter. Investors interested in registering for the company's conference call can do so using this link.
Mesoblast Price Performance
Shares of MESO stock traded down $0.62 during trading on Friday, reaching $16.61. 103,394 shares of the company's stock traded hands, compared to its average volume of 371,569. Mesoblast has a 1 year low of $1.91 and a 1 year high of $22.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The firm's 50-day moving average is $17.73 and its 200 day moving average is $11.69.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. Piper Sandler reissued an "overweight" rating and issued a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Jefferies Financial Group lowered shares of Mesoblast from a "buy" rating to a "hold" rating in a research note on Monday, December 23rd. Finally, Cantor Fitzgerald upgraded shares of Mesoblast to a "strong-buy" rating in a research report on Thursday, January 30th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $18.00.
View Our Latest Analysis on Mesoblast
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
